生物科技公司Viking治疗技术公司在试验中研制肥胖药物,报告损失49.6M Q2,但有900M现金和大量的投资者兴趣。 Biotech firm Viking Therapeutics, developing obesity drug in trials, reports $49.6M Q2 loss, but has $900M cash & significant investor interest.

Viking治疗公司(VKTX)是一家生物技术公司,重点开发新陈代谢紊乱疗法,在试验中使用一种有前途的肥胖药物,可以与诺沃·诺迪斯克和伊莱利等主要角色竞争。 Viking Therapeutics, Inc. (VKTX) is a biotech firm focused on developing therapies for metabolic disorders, with a promising obesity drug in trials that could compete with major players like Novo Nordisk and Eli Lilly. 尽管第二季度净亏损为4960万美元,但VKTX拥有超过9亿美元的现金和大量投资者利益,50个对冲基金持有4.791亿美元的合并股权. Despite a net loss of $49.6 million in Q2, VKTX boasts over $900 million in cash and significant investor interest, with 50 hedge funds holding a combined stake of $479.1 million. 其口服药物配方可能在市场上提供竞争优势。 Its oral drug formulation may offer a competitive edge in the market.